Smoking cessation 3: Nicotinic partial agonists in smoking cessation - Varenicline and cytisine
Cigarette smoking is the most preventable cause of illness, death, and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this third article in our series on smoking cessation in primary care, we look at the evidence for the use of nicotinic par...
Asıl Yazarlar: | Aveyard, P, Parsons, A, Begh, R |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2009
|
Benzer Materyaller
-
An integrated approach to pharmacotherapy in smoking cessation: the role of varenicline, bupropion, cytisine, and nicotine replacement therapy
Yazar:: Kacper Więcław, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01) -
The place of varenicline in smoking cessation treatment.
Yazar:: Aveyard, P
Baskı/Yayın Bilgisi: (2008) -
Smoking cessation 4: Antidepressants for smoking cessation - Bupropion and nortriptyline
Yazar:: Aveyard, P, ve diğerleri
Baskı/Yayın Bilgisi: (2010) -
Placebo-controlled trial of cytisine for smoking cessation.
Yazar:: West, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011) -
Nicotine receptor partial agonists for smoking cessation
Yazar:: Livingstone-Banks, J, ve diğerleri
Baskı/Yayın Bilgisi: (2023)